Log on / register
Feedback | Support | My details
  Quick Search
Current Opinion in Investigational Drugs
BioMed Central
PubMed Central
PubMed
  Jump to article
 vol.
page no.

Current Opinion in Investigational Drugs

Home



Current Opinion in Investigational Drugs, Volume 11, Issue 1 (January 2010)        [more info]

 
Current Opinion in Investigational Drugs is published monthly and delivers systematic and comprehensive coverage of the following therapeutic areas: Anti-infectives; Anti-inflammatory, immune-meditated and gastrointestinal; Cardiovascular, renal and metabolic; Central and peripheral nervous system; Oncological

Access to the full text or PDF of articles from Current Opinion in Investigational Drugs requires a subscription to the journal. Individual PDFs may be purchased by contacting ts.ids@thomson.com.


  previous issue

 



 

 

 


Paper alert
SA Antoniu, M Daneshtalab, S Doggrell, MJ Elices, RE Hurst, M Williams
Current Opinion in Investigational Drugs 2010, 11:1-7 (21December2009)
[Abstract] [Full text] [PDF]


Patent alert
HAM Mucke, P Norman, C Yeates
Current Opinion in Investigational Drugs 2010, 11:8-15 (21December2009)
[Abstract] [Full text] [PDF]


Drugs to treat fibromyalgia - The transatlantic difference
M Briley
Current Opinion in Investigational Drugs 2010, 11:16-18 (21December2009)
[Abstract] [Full text] [PDF]


The tetrahydrobiopterin pathway and pain
AM Naylor, KR Pojasek, AL Hopkins, J Blagg
Current Opinion in Investigational Drugs 2010, 11:19-30 (21December2009)
[Abstract] [Full text] [PDF]


COX-2 inhibitors as antidepressants and antipsychotics: Clinical evidence
N Mller
Current Opinion in Investigational Drugs 2010, 11:31-42 (21December2009)
[Abstract] [Full text] [PDF]


ICE/caspase 1 inhibitors and IL-1 receptor antagonists as potential therapeutics in epilepsy
A Vezzani, S Balosso, M Maroso, D Zardoni, F No, T Ravizza
Current Opinion in Investigational Drugs 2010, 11:43-50 (21December2009)
[Abstract] [Full text] [PDF]


FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels
S Petrosino, V Di Marzo
Current Opinion in Investigational Drugs 2010, 11:51-62 (21December2009)
[Abstract] [Full text] [PDF]


Neurobiological mechanisms of addiction: Focus on corticotropin-releasing factor
GF Koob, EP Zorrilla
Current Opinion in Investigational Drugs 2010, 11:63-71 (21December2009)
[Abstract] [Full text] [PDF]


Neurophysiological methodologies: Diagnosis of peripheral nerve disease and assessment of pharmacological agents
BC Cheah, MC Kiernan
Current Opinion in Investigational Drugs 2010, 11:72-79 (21December2009)
[Abstract] [Full text] [PDF]


Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea
MN Sabbagh, HA Shill
Current Opinion in Investigational Drugs 2010, 11:80-91 (21December2009)
[Abstract] [Full text] [PDF]


BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia
PB Fitzgerald
Current Opinion in Investigational Drugs 2010, 11:92-100 (21December2009)
[Abstract] [Full text] [PDF]


Almorexant, a dual orexin receptor antagonist for the treatment of insomnia
DN Neubauer
Current Opinion in Investigational Drugs 2010, 11:101-110 (21December2009)
[Abstract] [Full text] [PDF]

 

 

  previous issue

 








© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.